Singapore markets closed

Straits Times Index
3,348.87
+12.28(+0.37%)
S&P 500
5,277.51
+42.03(+0.80%)
Dow
38,686.32
+574.82(+1.51%)
Nasdaq
16,735.02
-2.08(-0.01%)
Bitcoin USD
69,209.98
+1,647.80(+2.44%)
CMC Crypto 200
1,488.02
+20.08(+1.37%)

FDMT Jan 2025 25.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

5.84

0.00

(0.00%)

As of 10:18AM EDT. Market open.

GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BSTCompany to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic
Simply Wall St.
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St.
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)
4D Molecular Therapeutics ( NASDAQ:FDMT ) First Quarter 2024 Results Key Financial Results Revenue: US$28.0k (down 91...